Journal
PHARMACEUTICALS
Volume 15, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/ph15101277
Keywords
pulmonary arterial hypertension; vasodilators; therapy; drug targets
Categories
Funding
- JSPS KAKENHI [22K06701]
Ask authors/readers for more resources
Pulmonary arterial hypertension (PAH) is a disease that leads to right-sided heart failure and death. Basic research has identified the decrease in levels of endogenous vasodilators and increase in levels of endogenous vasoconstrictors in PAH patients, leading to the development of therapeutic agents. Current treatments target specific pathways to improve prognosis.
Pulmonary arterial hypertension (PAH) is a disease in which stenosis or obstruction of the pulmonary arteries (PAs) causes an increase in PA pressure, leading to right-sided heart failure and death. Basic research has revealed a decrease in the levels of endogenous vasodilators, such as prostacyclin, and an increase in the levels of endogenous vasoconstrictors, such as endothelin, in patients with PAH, leading to the development of therapeutic agents. Currently, therapeutic agents for PAH target three pathways that are selective for PAs: the prostacyclin, endothelin, and nitric oxide pathways. These treatments improve the prognosis of PAH patients. In this review, we introduce new drug therapies and provide an overview of the current therapeutic agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available